IDH1 and central nervous system cancer: This finding is in stark contrast with the study conducted by Sanson et al. [48] for IDH1 (codon 132 only) wherein OS of grade IV gliomas (primary GBM) was better in IDH1-mutated GBMs than nonmutated ones (OS, 27.4 vs 14 months, respectively).